Monitor blood pressure, serum creatinine, and serum potassium levels within 2 to 4 weeks after initiating or increasing the dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB). ACEi or ARB therapy should generally be continued unless serum creatinine increases by more than 30% within 4 weeks of initiation or dose escalation.
According to FDA recommendations, metformin should not be used in men with a serum creatinine level ≥ 1.5 mg/dL or in women with a level ≥ 1.4 mg/dL, or in individuals over 80 years of age with decreased creatinine clearance. However, treatment with metformin is recommended in patients with type 2 diabetes (T2D), chronic kidney disease (CKD), and an estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m².
ADA/KDIGO Consensus Statements:
All patients with type 1 or type 2 diabetes and CKD should be managed using a comprehensive, individualized care plan developed collaboratively between healthcare professionals and the patient. This plan should focus on optimizing nutrition, physical activity, smoking cessation, and weight management. Evidence-based pharmacologic therapies should be implemented to preserve organ function, alongside additional treatments aimed at achieving intermediate targets for glycemic control, blood pressure, and lipid management.
%20Aspirin%20325%20mg%20followed%20by%2081%20mg%20daily.%20P2Y12%20Antagonist%20Loading%20(Clopidogrel%20or%20Ticagrelor)%20followed%20by%20Maintenance.%20Anticoagulant%20therapy%20(Unfra.jpg)
Myocardial Infarction (MI)
Myocardial infarction is classified into five types based on the underlying etiology and clinical circumstances:
Type 1 MI: Spontaneous myocardial infarction resulting from ischemia due to a primary coronary event, such as plaque rupture, erosion, fissuring, or coronary artery dissection.
Type 2 MI: Myocardial ischemia secondary to an imbalance between oxygen supply and demand. This may occur in the setting of increased demand (e.g., severe hypertension) or decreased supply (e.g., coronary artery spasm, embolism, arrhythmias, or hypotension).
Type 3 MI: Sudden unexpected cardiac death, including cardiac arrest, often with symptoms suggestive of myocardial ischemia and presumed new ECG changes or ventricular fibrillation before biomarkers can be obtained.
Type 4a MI: Myocardial infarction associated with percutaneous coronary intervention (PCI), defined by an elevation in cardiac troponin (cTn) values >5 times the 99th percentile upper reference limit (URL), along with evidence of ischemia.
Type 4b MI: Myocardial infarction associated with documented stent thrombosis.
Type 5 MI: Myocardial infarction occurring in the context of coronary artery bypass grafting (CABG), with cTn elevation >10 times the 99th percentile URL and supporting clinical or imaging findings.
Infarct Location and Clinical Implications
Right Ventricular (RV) Infarction: Most commonly results from obstruction of the right coronary artery or a dominant left circumflex artery. It is characterized by elevated right ventricular filling pressures, which may be accompanied by severe tricuspid regurgitation and reduced cardiac output. RV infarction can significantly impair hemodynamics.
Inferoposterior Infarction: Often leads to some degree of RV dysfunction in approximately 50% of cases and hemodynamic compromise in about 10–15%. In patients with inferoposterior infarction, elevated jugular venous pressure in conjunction with hypotension or shock should prompt consideration of RV involvement. RV infarction in the setting of left ventricular infarction markedly increases mortality risk.
Anterior Infarction: These infarcts are typically larger and are associated with worse outcomes compared to inferoposterior infarctions. They usually result from obstruction of the left coronary artery, particularly the left anterior descending artery. In contrast, inferoposterior infarctions are commonly due to right coronary artery or dominant left circumflex artery occlusion.
Cholangitis
Cholangitis was first defined in 1877 by Jean-Martin Charcot, who described the pathognomonic triad of fever, right upper quadrant pain, and jaundice. Today, cholangitis is defined as the presence of increased hepatic intraductal pressure along with concurrent infection of the obstructed bile ducts.
Chole: Derived from the Greek word “cholē,” meaning bile.The pathogens most commonly identified as causative agents of acute ascending cholangitis are gram-negative and anaerobic organisms. The most common pathogens include Escherichia coli, Klebsiella, Enterobacter, Pseudomonas, and Citrobacter.
Iatrogenic introduction of bacteria often occurs following endoscopic retrograde cholangiopancreatography (ERCP) in individuals with biliary obstruction.
Charcot's Triad: The classical triad (fever, right upper quadrant pain, and jaundice) has high specificity (95.9%) but low sensitivity (26.4%).
Tokyo Guidelines (2018): The sensitivity of the Tokyo guidelines is 100%, with a specificity of 87.4%.
.%20Hypertriglyceridemia,%20Hyperlipidemia,%20Lipoprotein%20x%20accumulation%20(e.g.,%20Primary%20biliary%20cirrhosis)%20Familial%20h.jpg)
%20group%20(table%201)%20%5B7%5D.%20They%20include%20the%20following%20%E2%97%8FDyspnea%20at%20r.jpg)
Thyroid Storm
